• With COPD, limited lung function
  • Makes breathing more difficult
  • WITH COPD, LIMITED LUNG FUNCTION
    MAKES BREATHING MORE DIFFICULT

  • TUDORZA can help

  • Why Tudorza?
  • Efficacy
  • Safety
  • The Pressair
    Inhaler

Why Tudorza?

TUDORZA is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis
and emphysema.1

Statistically
Significant
Bronchodilation

For the long-term maintenance treatment of bronchospasm in patients with COPD, TUDORZA provides statistically significant improvements in bronchodilation that are consistent over time.1

Tudorza
Safety Profile

Learn about the safety profile of TUDORZA, including information on common side effects and
long-term studies.

The Tudorza
Pressair Inhaler

A preloaded, multiple-dose,
dry powder inhaler. See complete step-by-step Instructions for Use in the full Prescribing Information.1

INDICATIONS AND USAGE

TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder) is an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

IMPORTANT SAFETY INFORMATION

  • TUDORZA PRESSAIR is not indicated for the initial treatment of acute episodes of bronchospasm (ie, rescue therapy).
  • Inhaled medicines, including TUDORZA, may cause paradoxical bronchospasm. In addition, immediate hypersensitivity reactions may occur after administration of TUDORZA. If either of these occurs, treatment with TUDORZA should be stopped and other treatments considered.
  • TUDORZA should be used with caution in patients with narrow-angle glaucoma or urinary retention. Instruct patients to consult a physician immediately should any signs or symptoms of narrow-angle glaucoma or prostatic hyperplasia or bladder-neck obstruction develop.
  • Patients with a history of hypersensitivity reactions to atropine should be closely monitored for similar hypersensitivity reactions to TUDORZA. Use with caution in patients with severe hypersensitivity to milk proteins.
  • The most common adverse reactions (≥3% incidence and greater than placebo) were headache (6.6% vs 5.0%), nasopharyngitis (5.5% vs 3.9%), and cough (3.0% vs 2.2%), for TUDORZA vs placebo, respectively.

Please also see the full Prescribing Information.

CLOSE  X

References

  1. TUDORZA PRESSAIR (aclidinium bromide inhalation powder) Prescribing Information. Forest Pharmaceuticals, Inc. St. Louis, MO.
  2. Data on file. Forest Laboratories, Inc.
  3. Kerwin EM, D’Urzo AD, Gelb AF, et al, on behalf of the ACCORD 1 study investigators. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD. 2012;9:90-101.
Thank you for visiting CLOSE  X
You are now leaving TudorzaHCP.com

Please note: Forest Laboratories, Inc. is not responsible for the content or services on the site you will now visit.
GO BACK     CONTINUE